Pathos AI in BMS, Tempus Alzheimer's deal; BMS leads $237 million round

The Pathos AI announcement sits alongside other news in the same briefing from Bristol Myers Squibb, which also disclosed a patient death in its Phase I Breakfree-2 trial of CAR-T therapy zola-cel for multiple sclerosis. The company said the death, from septic pneumonia 44 days after infusion, was unrelated to its earlier voluntary pause on zola-cel studies, and that no additional Grade 5 events had occurred across the 190 patients treated in its Phase I autoimmune programs. That disclosure and the Pathos collaboration appear in the same briefing without being linked.

The Pathos deal pairs an AI platform, Foundry, with BMS's neuroscience portfolio and adds Tempus AI as a partner on dataset building. The structure — a $237 million round led by BMS, a post-money valuation of approximately $3 billion, and three-year exclusive rights for BMS — suggests the pharma company is buying both an equity stake and platform access, while Pathos secures a named pharmaceutical partner for Alzheimer's work. Whether the partnership's dataset and agentic capabilities translate into pipeline progress is not addressed in the announcement.